Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. (2022)
Attributed to:
Optimising therapeutic strategy in psoriasis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(21)00333-7
PubMed Identifier: 34778846
Publication URI: http://europepmc.org/abstract/MED/34778846
Type: Journal Article/Review
Volume: 4
Parent Publication: The Lancet. Rheumatology
Issue: 1
ISSN: 2665-9913